Original language | English (US) |
---|---|
Pages (from-to) | e96-e97 |
Journal | Ophthalmology |
Volume | 126 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2019 |
ASJC Scopus subject areas
- Ophthalmology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Ophthalmology, Vol. 126, No. 12, 12.2019, p. e96-e97.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
AU - HAWK and HARRIER Study Investigators
AU - Dugel, Pravin U.
AU - Koh, Adrian
AU - Ogura, Yuichiro
AU - Jaffe, Glenn J.
AU - Schmidt-Erfurth, Ursula
AU - Brown, David M.
AU - Gomes, Andre V.
AU - Warburton, James
AU - Weichselberger, Andreas
AU - Holz, Frank G.
N1 - Funding Information: G.J.: Research funds – Alcon/Novartis, during the conduct of this study; Consultant – Sanofi, Heidelberg Engineering, Novartis, pSivida, Regeneron, outside the submitted work. Financial Disclosures: The authors made the following disclosures: D.B.: Grant – Alcon, during the conduct of this study; Grants – Novartis, Regeneron, Santen, Ophthotech, Clearside Biomedical, Aerpio, Allergan, Samsung, Thrombogenics, Heidelberg, NEI, Chengdu Kanghong Biotech Co, Ltd, Adverum, Regenxbio, Allegro, OHR, Tyrogenix, outside the submitted work; Personal fees – Alcon, during the conduct of this study; Personal fees – Novartis, Regeneron, Bayer, Santen, Clearside Biomedical, Allergan, Samsung, Thrombogenics. Heidelberg, Optos, Chengdu Kanghong Biotechnology Co., Ltd, Adverum, Regenxbio, Google/Verily, Carl Zeiss Meditec, Coda Therapeutics, Janssen, Johnson & Johnson, OHR, Notal Vision, Optovue, Pfizer, Senju Pharmaceuticals, Stealth Biotherapeutics, Tyrogenix, outside the submitted work. F.H.: Grant – Alcon/Novartis, Heidelberg Engineering, Genentech/Roche, Allergan, Pixium, Nightstar, Optos, Carl Zeiss Meditech, during the conduct of this study; Personal fees – Alcon/Novartis, during the conduct of this study; Consulting – Heidelberg Engineering, Zeiss, Acucela, Genentech/Roche, Allergan, Boehringer-Ingelheim; Bayer Healthcare, LIN Bioscience, Pixium, Gallmedix, during the conduct of this study; Speakers bureau – Bayer Healthcare, Genentech/Roche, Zeiss, Heidelberg Engineering, outside the submitted work. Y.O.: Grant – Novartis Pharma, during the conduct of this study; Personal fees – Novartis Pharma, during the conduct of this study; Grant – Santen, outside the submitted work; Personal fees – Bayer, Santen, Senju, Kowa, Wakamoto, Hoya, outside the submitted work.
PY - 2019/12
Y1 - 2019/12
UR - http://www.scopus.com/inward/record.url?scp=85074786150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074786150&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2019.08.016
DO - 10.1016/j.ophtha.2019.08.016
M3 - Letter
C2 - 31759510
AN - SCOPUS:85074786150
SN - 0161-6420
VL - 126
SP - e96-e97
JO - Ophthalmology
JF - Ophthalmology
IS - 12
ER -